International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 1100-1110 www.ijprajournal.com ISSN: 2456-4494

"A Review on Nanoparticles in Cancer Therapy"

Aniket.B.Shinde*, Dr.Sanjay.K.Bais
1-Student ,2-Professor & Principle
B.Pharmacy
Fabtech College of Pharmacy, Sangola, Solapur, India, Maharashtra

Date of Submission: 05-12-2025 Date of Acceptance: 12-12-2025

ABSTRACT-:
With its intricate pathophysiology, However, a number of issues restrict their efficacy, including cytotoxicity, lack of selectivity, and multidrug resistance. Significant improvementsin cancer diagnosis and treatment have been made possible by the development innanotechnology. Nanoparticles (1–100 nm) are useful instruments in the therapy of cancerbecause of their special benefits, which include enhanced permeability and retention(EPR)effect, decreased toxicity, improved stability, biocompatibility, and precise targeting.
The unique drug-delivery methods of the many primary types of nanoparticles that havebeenproduced take advantage of the characteristics of malignancies and their microenvironment. In addition to overcoming multidrug resistance, nanoparticles solve a number of thedrawbacks of conventional cancer treatments. New mechanisms of multidrug resistanceandrelated nanoparticle-based methods are still being investigated. Similar Phrases still Limitedto in vitro And vivo Study, only a small Nanotechnology have received clinical approval, despite the fact that nano-formulations provide promising therapeutic uses and have openednew possibilities in cancer treatment. In this study, we go over authorized nanotherapeutics, targeting tactics, and various kinds of nanoparticles that are pertinent to cancer. Wealsodiscuss the benefits, difficulties, and future directions of these technologies' clinical translation.[1]

Keywords: Antineoplastic, cryosurgery, Multiple Drug, nanoparticles, cancer

I. INTRODUCTION.

The invasiveness and unregulated, random cell division of Collective Noun diseases Tumor, Neoplasm, Growth of mass are what set them apart. Bad lifestyle choices including smoking, eating poorly, being stressed, and not exercising have a big influence on cancer riskassessment.

Determining the function of genome repairing genomes, cancer suppression gene activitytrends and proto-oncogene mutations has proven challenging, despite the fact that theseextrinsic variables have been identified as important drivers of cancer. Just 5 to 10%ofmalignancy cases are caused by genetic factors. Growing older is an important danger factorfor malignancy and many other forms of cancer. One of the leading causes of deathworldwide, cancer is a serious public health issue. The National Cancer Institute projectsanextra 1.9 million cases by the close of 2021. The conventional methods of treatingcancerinclude chemotherapy, surgery, radiation treatment, specific therapy, chemotherapy, immunotherapy, and hormone therapy. However, radiation and chemotherapy cancausecytotoxicity and hypostasis.

The most common side effects are neurological conditions, bone marrow suppression, fatigue, skin and gastrointestinal problems, and hair loss. There are also certain drug-specific adverseeffects, such as heart and lung damage caused by anthracyclines and bleomycin. Withtheadvent of focused therapy, precision therapy has grown. However, A inevitable adverseconsequences continue to occur, to multiple drugs as multidrug resistance. That lowerstreatment efficacy. In addition to avoiding far away metastases By reducing the chanceofrecurrence, immunotherapeutic medications have demonstrated promise in the treatment oforiginal cancer. However, one of immunotherapy's targets is autoimmune illness. primarynegative effects. nanoparticles to overcome the limitations of existing medicinal methods. Nanoparticle-based systems for drug delivery have demonstrated promising in treatment andmanagement of cancer due to their precise metabolism, targeting, decreased unwantedeffects, and drug resistance. Many nanotherapeutic medications have been produced andwidelymarketed as a result of advancements in nanotechnology, and around 2010, more morehavereached the clinical stage. By lowering the mechanisms underlying drug resistanceandoffering an opportunity for drug

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 1100-1110 www.ijprajournal.com ISSN: 2456-4494

combination therapy, nanotherapeutic drugs have enhanceddrug delivery methods and eradicated tumours multidrug resistance (MDR).



Figure 1: Nanoparticles for cancer therapy (Graphical Abstract)

A characteristic Out of Both the therapeutic drugs and the specified nanoplatforms needtoexercise prudence. antibodies, prolonged toxicity, neurotoxicity, and the absence of invitromodels that accurately mimic the stage in vivo are among the drawbacks that havebeenexplored. Even so,"nano-vaccines" And "artificial APCs" Have demonstrated superiorsuperiority over traditional immunotherapy, their Health care performance of still subpar. These novel methods' tolerability and safety must Is investigated. Furthermore, creatingimmunomodulatory factor-loaded NPs" might increase Is efficacy of immunizationvaccinations. In the context of proteomics studies "mechanism of cancer origin, MDR, occurrence" advances, this anticipated is more NP-based medications available for use[3] emerging sector.

Contrary to the vast number of studies, only a limited number of NP-based medicationarecurrently in use, the most are still in the exploratory stage, and a small number are doingclinical studies.

II. NANOPARTICLES

To put it another way, nanoparticles (NPs) are particles that have a single dimension of lessthan 100 nm and unique properties that are normally missing from larger amounts of thesame substance. The unique features, differences, sub-micron size, and improved targetingmechanism of these resources are highly significant in transdisciplinary disciplines. Recent research has shown that the increased blood flow and retention (EPR) effect is improvedbyNPs' deep tissue penetration. Additionally, the surface properties influence bioavailabilityandhalf-life by skilfully traversing epithelial fenestration. For instance, NPs coated with the hydrophilic polymer polythene glycol (PEG) reduce opsonization and prevent the immunesystem from eliminating them.. Furthermore, the rate of release of the drug or active moietycan be optimized by modifying the features of the particle polymer. The unique characteristics of NPs collectively control their therapeutic efficacy in the management and[4] treatment of cancer.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 1100-1110 www.ijprajournal.com ISSN: 2456-4494



Figure 2. Classification of NP Synthesis (a) top-down and (b) bottom-up approaches.

1. Production of NPs-:

The sizes, shapes, and arrangements of the NPs are diverse. This is achieved by a varietyofsynthetic methods. Those methods may be loosely divided into two categories.: 1.a methodical approach
2. a grassroots methodology. These techniques can be further divided into a wide rangeofsubclasses according on their behaviour.

2. Bottom-up approach-:

This approach is referred to as the constructive technique since it produces content that includes atoms, clusters, nanoparticles, and same compounds. Among the often Amongthemethods used include chemically vaporising (CVD), rotating, sol-gel synthesis, laser ignition, a plasma or flame sprayed production, and ogenesis.

3. Top-down approach-:

By decreasing bulk materials or compounds, this process—also known as the destructiveapproach—creates NPs. When a larger molecule breaks down, smaller units are createdthenNPs. This includes processes comprising sputtering, chemical etching, mechanical milling, thermal breakdown, laser ablation, nanolithography, and electro-explosion. Surprisingly, NPs' morphological characteristics, their Changes to size, shape, and charge can be madebyvarying circumstances and other parameters for synthesis. Moreover, Therefore, in order tosynthesize the required NPs. [5]

2. Mechanisms of Cellular-:

Identifying Effective cancer treatment requires the development or engineering of a drugorgenetic system of administration which can precisely target tumour cells while maintaininghealthy, normal cells. This enhances therapy effectiveness and protects health. NPs canbedelivered into the microenvironment of cancer cells (TME) in a systematic way toachievethis. In order to avoid non-specific targeting, these realities impose limitations onsize, biological compatibility, and other aspects.

NPs' surface chemistry as well. However, internalizing a medication called NPinthecytosolic molecule alone does not ensure that it will reach intended location within thecell. To enable nuclear or cellular targetingSpecial engineering and optimisation are needed. Pharmacological targeting designed based on NPs has been the subject of several studiestodate, and more are being developed. These nanocarriers should, in general, have a fewkeycharacteristics, such as 1) the ability to remain stable in the circulation until they reachedtheir target, TME 2) to escape being eliminated by the system of reticuloendothelial cells(RES), 3) to elude the system of mononuclear phagocytes (MPS), 4) to congregate inthetumor micro environment (TME) after passing through the tumor blood vessels,and5) toenter the tumor fluid at
Physicochemical characteristics, pathophysiological qualities, and surface functionalizationare important factors that regulate the NP process. cantered on drugs. NPs with sizes between10 and 100 nm are generally believed to effectively treat cancer. 3.1 Passively FocusedThefirst macromolecule to build up in the tumor was found to be a modest quantity of ma

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 1100-1110 www.ijprajournal.com ISSN: 2456-4494

intheselate 1980s. This preferred distribution was shown in later studies. windows is damagedThisTerm "enhanced permeation and retention effect" To deal with hypoxia, growing Cancer cellsfrequently establish novel veins and consume those that already existed. The higher aperturesnascent vessels. possess low tumour blood vessel perm-selectivity and are leakier thanbloodfrom healthy sources.

Because of this flawed and rapid angiogenesis, there is NPs are able to exit these vesselsofblood and eventually gather inside malignant cells due to the lack of extravasation protection. Extracellular plasma, or extracellular fluid, for short, frequently drained into lymphatic bloodvessels in solid tissue at a rapid speed ranging from 0.1–2 µm/s on average. guaranteeingongoing renewal and drainage. Because when a tumour grows, the lymphatic systemisdisrupted and less interstitial fluid is absorbed. This feature helps NPs stay in the tumorinterstitium since they are not removed but rather kept there. It special quality is no relevant substances they are rapidly eliminated from malignant cells and have short half-lives.
[6]

3.1.1 Illustrations of Passive Targeting

A taxane are best types of pharmaceuticals for treating cancer. Paclitaxel has been showntobe beneficial against a range of cancers. Microtubules are stabilized by the anti-microtubuledrug Abraxane®, which prevents depolymerizationIn natural rats, cellular process acceptabledose (maximum tolerated dose) of the medication PM® were threefold greater.due toanunusual arrangement of microtubules and many asters caused by the well-knowntaxanepaclitaxel. This is approved for the treatment of MBC in South Korea. Phase II clinical research is now being conducted Treatment for cancer of the pancreas in the UnitedStatesThe anti-cancer medication DaunoXome® (also known as daunorubicin; Gilead Science, Diatos, Inc.) inhibits the proliferation of malignant cells. Daunorubicin is the active substance. This specific liposome formulation of daunorubicin is distinct. [7]

Additionally, tumor cells grow irregularly due to the heterogeneous blood supply; Aunevenleakage not only slows down the neovascularization process but also increases interstitial pressure and hinders the transfer and storage of medications. However, the EPRphenomenoncan be controlled mechanically or chemically. Radiation, heat, bradykinin andothersubstances are among them. However, there are a number of limitations and contraindications. The term "ligand-mediated targeting" explains the method of targeted. carbohydrates andthereceptor of(EGFR), which ligands, are the most frequently researched receptors. Whenligand-target interaction occurs, the membrane infolds and NPs internalize via receptor-mediated endocytosis. This process improves their ability to penetrate cells. Transferrinis oneof the most abundant in cells. Most tumor cells have been demonstrated to overexpress thesereceptors, which are not as highly expressed in healthy cells.

Therefore, by adding ligands that particularly target transferrin, we can modify theNPs. Furthermore, tumor blood vessels are adjacent to these cells. This strategy can cause hypoxiaand necrosis by preventing the cancer cells from receiving blood supply. Tumour organs havebeen shown to have a greater acidification than normal ones. The cell begins overproducingpp to deal with the harsh circumstances, which causes the extracellular region to become[9] more acidic by releasing too much of acid from the cells.

3.2.1 Examples of Active Targeting-:

Many types of cancer, especially those with squamous tissue histology, possess the tyrosineoperator (TK) receptor EGFR of the ErbB family. SCC in humans can be targetedbynanoparticles of gold including anti-IgG-PEG-AuNPs and anti-EGFR PEG-AuNPs. ThedrugHerceptin® targets the excessively expressed recombinant EGF receptor 2- (HER2) on the outer coating of cancerous breast cells. HER2-targeted polythene glycol lipid paclitaxel wasdeveloped to reduce cardiovascular disease, a recognised side effect of the anthracyclines. Tumour endothelium expresses vascular cell adhesion molecule-one (VCAM-1), aglycoprotein implicated in angiogenesis. A research found NPs to attack carcinoma of thebreast .

VCAM-1, a camera demonstrating possible uses. DNA synthesis requires folic acid, sometimes referred to as vitamin B9. Through the folate receptor, cells take in folicacid. Liquid cancerous cells overexpress FR-β, whereas cancerous cells express more FR-α, thealpha variant of the folate receptor. Folate receptors have recently been targeted byNPsincertain cancer therapies. Nanoparticle-Based Cancer Therapy: Medication deliverytechniques frequently employ inorganic, synthetic, and nanoparticles with hybrid properties.

4.1 Polymeric Nanoparticles-:

A research found that indomethacin-laden particles significantly reduced growth of tumoursand enhanced survival in an animal transgenic glioblastoma model with the endothelial membrane of cells of the brain and blood vessel barrier (BBB). PNPs, or polymericnanoparticles, are "colloidal macromolecules" having a particular structural architecturecomposed of several monomers with sizes ranging from 10 to 1000 nm. The medicinal product is either contained or attached to the outside of NPs to forma small sphereornanotechnology capsule in order to achieve controlled drug distribution in the target. PNPswere made from nonbiodegradable polymers such as polystyrene, polyacrylamide, andpolymethylmethacrylate (PMMA). But it was poisonous. In recent years, The proteinsalbumin, chitin, polylactic acid, amino acid polymers, and alginate are examples ofbiodegradable polymers. because they have been shown to enhance medication release, reduce toxicity, and improve biocompatibility. Empirical research has shown that coveringPNPs with polysorbates can generate their surfactant action. Interactions between NPs areimproved by external coating..[10]

4.2 Dendrimers -:

Typical this polyethylene glycol (PEG), polypropylene (PPI), polyamidoamine (PAMAM), and triethanolamine (TEA). MDR management was the original purpose of a PAMAMdendrimer. DNA assembled, PAMAM There are numerous ways to describe dendrimers. Thedevelopment of In mice receiving one drug therapy, dendrimers were found to significantlyslowed the development of epithelium carcinoma xenografts. 4.3 small beads Monoclonal antibodies are widely employed in cancer therapy because to their special targeting properties.

Dendrimers are spherical polymeric macromolecules with a recognizable hyperbranchedstructure. The massively branching structures of dendrimers are their defining feature. Theproduction of dendrimers is often initiated by a reaction between an ammonia coreandAcrylic acid. This procedure produces “tri-acid" molecule, which subsequently reacts withEdamine to form "tri-amine," result of way. Triethanolamine (TEA), polyethyleneglyc (PEG), polypropylenimine (PPI), and polyamidoamine (PAMAM) are frequently used inseveral dendrimers.[11]

4.3 Immuno Nano-system -:

Preprints Extracellular vesicles. Extracellular vesicles (EVs) are phospholipid vesicles withtwo layers and a size ranging from 50 to 1000 nm. Many cell types continuously dischargeEVs of various sizes, compositions, and origins.These are often employed in conjunctionwith exosomes because their lipids and molecules are very similar to those of the originatingcells. A delivering anti-tumor drugs and cytotoxic drugs to the designated sites, Theyact astransporters of organic matter. Because ExoDOX improves cytotoxicity while minimizingcardiotoxicity, When compared to doxorubicin, it has produced exceptional outcomes inthetreatment of breast cancer. Exosome NPs outperform synthesised NPs in terms of intrinsicbiocompatibility, intracellular communication, and chemical stability. However, a number ofissues must be addressed, including the lack of precise criteria for exosomal separationandpurification.

4 .4 Liposomes-:

Because of characteristics including biological inertness, low intrinsic toxicity, and moderateimmunogenicity, liposomes are unique. Because of their enhanced bioavailability andhigheranti-tumor action, liposomes are a perfect delivery system for medications includingnucleicacid, paclitaxel, and doxorubicin. MBC is treated using approved liposome-baseddaunorubicin formulations called Myocet® and Doxil®. However, disadvantages suchdecreased encapsulation efficiency, The use of liposome-derived Nanoparticles is limitedbytheir limited shelf life, weak cells retention, and rapid elimination by Mps..

4.5 Nanoparticles of solid lipids -:

(SLN) Such colloid tiny carriers, which range in particle size between 1 nmto 100nm, arecomposed of a lipid single layer, water, and an agent that emulsifies. The term"zero-dimensional nanomaterials" describes this. Lipids include waxes, steroids, fattyacids, triglycerides, and other compounds. PEGylated fatty acids The "micelle-like structure"ofSLNs, which distinguishes them from conventional liposomes, Positive results havebeenseen when doxorubicin and SLN are combined.

4.6 Carbon Nano-materials -:

They are widely used in medical sectors due to their optical, mechanical, and electromagneticcharacteristics, in addition to their biocompatibility Carbon particles are capable of packagingmedicines via π-π stacked due to their ability to repel moisture. A 2-dimensional crystal including a carbon sheet hybridised with sp2,"graphene" In breast cancer cells models, GO-doxorubicin was found to have greater anti-cancer activity. Fullerenes are enormous carbon-cage molecules made up of carbon allotropes that can take on many shapes such as spheres, tubes, and ellipsoids. They are the most studied nanocarriers because of their similarstructural, physical, chemical, and electrical properties. When utilised in photodynamictherapy, they produce oxygen species and have a threefold yield. Tumour cells showedfavourable photodynamic effects from fullerenes being treated with PEG. The cylindrical tubes known as carbon nanotubes or carbon rolls, were found in the late 1980s. Theyaredivided either two groups: CNTs with one wall & CNTs that are constructed with several walls. They were formerly employed in thermal ablation treatment or as conduits for DNA transfer.[11]

4.7 Quantum dots-:

Typically tiny semiconductors, quantum dots have a variety of Their narrowemissionbands, absorption, and good photostability enable a wide range of applications. Regarding imagingbiology These are divided into four categories according to co2

1) Atoms made of oxygen
2) nano-diamond Atoms dots.

Atoms made are being researched for their potential to treat cancer together with imagingofbiological tissues. The most commonly utilized due to inherent biodegradability andspeed, Atomic dots of diamond are being eliminated. For example, the combination of doxorubicinand quantum dot aptamer is intended to treat prostate cancer. cells. However, there aren't enough effective ways to make quantum.

4.8Metallic nanoparticles-:

Because of their extraordinary. photothermal, & optical properties, Metal-Based nanoparticlesbeing study by for "biological imaging" & Targeted DDS. Many of the most extensivelygold, & silver nanoparticles The controlled Additionally, because of their visible light extinctionbehavior, NP may be monitored. routes inside each cell. It has been shown that "Gold-on-silica nanoshells with anti-HER2 functionalization" The iron oxide nanoparticle Combidex®formulation is being tested in the latter stages of clinical studies for the detection of nodal metastases. Iron deficiency anaemia is treated with Feraheme®, an iron oxide nanoparticlesformulation that contains ferrumoxytol. It is used for the treatment distant metastasesofprostate and testicular cancer and was approved by the FDA in June 2009.

4.10Calcium phosphate nanoparticles-:

Calcium phosphate nanoparticles do not have any serious adverse effects, are biodegradable, and are compatible with biology. antibiotics, contraception, a hormone called insulinas well as development chemicals are therefore administered through them. They are alsousedtotransport DNA from plasmids and oligonucleotides. Calcium and glycerol formulations of a"nanoliposome liposome" have shown less toxicity and enhanced transfection. Attributes

4.11Silica nanoparticles-:

Although silica is an essential component of many natural products, research on its biological uses is relatively new. A group of surface amino-silicans It has been discoveredthat functionalized silica nanoparticles, which are readily accessible and have minimal toxicity, may successfully implant Cos-1 cells [113]. Because of their exceptional pharmacokineticscharacteristics, mesoporous mica nanoparticles (NPs) are thought to be effective drugcarriers.

They are often employed in immunotherapy. According to a study, mesoporous nanoparticles[12] of silica coated with the drug camptothecin were absorbed by colorectal cancer cells.

4.12Cyclodextrin nanosponges-:

Usually, cyclodextrins are employed as stabilisers to boost NPs' ability to load drugs. Nanosponges are tiny, mesh-like structures. Paclitaxel-loaded cyclodextrin nano sponges havedemonstrated strong cytotoxic actions in MCF-7 blood cell cultures. Similarly, usingcyclodextrin-based nano sponges to manufacture the chemical improves its long-termstability & solubility.

5. Nano-Molecule in Immunotherapy-:

The immune system has a major impact on the development and spread of cancer. Immunotherapy has changed this route of cancer is treated. Immunotherapy employsanumber of techniques, including "immune checkpoint

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 1100-1110 www.ijprajournal.com ISSN: 2456-4494

blockade therapy," "immune system,""vaccine therapy," and "chimeric antigen receptor (CAR)-T cell therapy." "Nano-vaccines,"

"aAPCs (artificial "immunosuppressed TME targeting"), and "antigen-presenting cells"areexamples of NP-based immunotherapy.

Supplying antigen-presenting cells with "tumor-associated antigens" and "adjuvants," suchasDCs or dendritic cells, is a specialty of nanovaccines. They can also be employedasadjuvants to enhance "APC antigen presentation" and promote DC maturation, whichactivates cytotoxic T-cells with anti-tumor characteristics. The ability of liposomes, PLGANPs, and gold NPs to deliver TAAs into DC cytoplasm is found. Mesoporous silica is theinorganic material that is most prevalent. NP's adjuvant activity has stimulatedtheimmunological response of artificial APCs. interact directly with MHC-antigen complexesthat adhere to T cells. Furthermore, by binding to co-stimulatory receptors, they activateTcells. NPs can also be used to target immunosuppressed TME.

immunological treatments. This is achieved by concentrating on important TMEcell types, including as "myeloid-derived suppressor cells," "tumor-regulatory T cells," and "associatedmacrophages (TAMs)" (MDSCs). Furthermore, it has been demonstratedthat chemoimmunotherapy combined with an effective cancer treatment approach is effective. Forinstance, studies have shown that co-loading Nutlin-3a, a cytokine and chemotherapeuticdrug present in "spermine-modified acetylated Dextran (AcDEX) NPs, enhancedtheproliferation of cytotoxic CD8(+) T cells and triggered an immune response." "Programmedcell death protein 1 (PD-1)" and "programmed cell death death" Ligand 1 (PD-L1) is oneofthe key immunological checkpoints. Therefore, immune checkpoint NPs are used totarget these with inhibitors. Traditional immunological responses to PD-L1/PD-1 checkpoint inhibitors were not consistent, according to a study. Taking the interaction into consideration[`13]
to boost the likelihood

6. Nanoparticles in cryosurgery-:

Cryosurgery is a state-of-the-art procedure in which cancer tissue is frozen to death. Somedownsides, such as damage to nearby cells and inadequate freezing capabilities, must be addressed even if this is less intrusive and causes intraoperative bleeding and postoperativecomplications. The advancement of nanotechnology has made it feasible to use NPsincryosurgery. The primary process As part of nano-cryosurgery, NPs with specific propertiesare delivered into the cancer cells. owing to freezing The ice that accumulates inside thecellsduring this process causes damage to them. With NPs, this important process canbesuccessfully finished. It's hot Utilizing NPs' conductivity is feasible.

characteristic that significantly damages cancers by freezing the malignant tissue. Theyalsocool down rapidly, and the "growth" may be controlled. direction" and "the directionof theice ball." There is a considerable chance it is cooling will injure healthy tissue. whencryosurgery is impractical because of the tumor's place or if other neighboring The tissues areunder danger.. Phase NP-based altering materials (PMs) have recently been Used to safeguard[14] neighbouring normal, healthy tissue.



Figure 6: Diagrammatic representation of NPs in cryosurgery.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 1100-1110 www.ijprajournal.com ISSN: 2456-4494

7. Mechanism of Nps in Reducing Sensitivity to Drugs-:

Resistance to medication is one of the biggest and most challenging parts of managingand treating cancer. It overcomes all types of cancer and available treatments. Whenillnesses become resistant to treatment, it's known as resistant to drugs.drug Resistancethat develops following a specific anti-tumor treatment is known as acquired resistance. This sort of resistance can be caused by changes in the TME following therapyorthedevelopment of novel mutations. Nanoparticles have the ability to co-encapsulate awiderange of therapeutic drugs due to their outstanding properties.

7.1 A Targating Efflux -:

These drugs' primary function is to lower concentrations by being pushed out of cells bytransporters. A specific efflux transporters that resistant to chemotherapy cancer cells enhanceis protein P P-gp.

In contrast to diffusion, NPs "endocytose" the cell to absorb at the drug "perinuclear site."What NPs can dodge as they are situated active Effluxion Pump. Furthermore, by NPs caneffectively evade Effluxion pumps by modify drug release regulation, such as by employingredox and low pH as triggers. Combine therapy other Effluxion tactic is circumvent multipledrug resistance. Another viable option would be to inhibit the transporter's expressivenessrather than simply avoiding them. NPs can contain multiple medications in a singledrugcarrier.

A new study found that using NPs that transport paclitaxel and COX-2 inhibitors at thesametime might erase multiple resistant treatments in breast carcinoma cells. Lung cancer cellsexhibit treatment resistance in a similar manner. has been effectively resolved by usingsilica[15]
nanoparticles encasing miRNA-495 and doxorubicin.

7.2 Targeting apoptotic

Path A faulty apoptotic pathway causes cancer cells to proliferate and become more resilient. "Deregulation of Bcl" increases drug resistance by triggering the faulty apoptotic pathway. 2." and "NF-κB, or nuclear factor kappa B." pro-survival proteins can be study the most is

could that target of a resistance of drug reversal. To circumvent this, a conventional approachis to co-deliver "Bcl-2 siRNA and chemotherapeutics" via NPs. fighting "drug resistancemediated by apoptotic pathways" by both suppressing anti-apoptotic proteins and activatingpro-apoptotic factors. The combination of paclitaxel with ceramide, for instance, is anexcellent example. Ceramide brings the expressiveness back.due to the significant therapeuticeffects that paclitaxel and ceramide combined have shown. efficiency in models of drugresistance in cancer.

A similar study was carried out utilizing planetary ball milled nanoparticles combinedwithfolic acid, docetaxel, and resveratrol-encapsulated prostate cancer cells that were resistant tomultiple drugs. This was accomplished by inhibiting the synthesis of genes that stop[16]
apoptotic and disabling ABC transportation indicators.

7.3 Targeting Hypoxia-:

A lack of oxygen is another factor that contributes to multiple medication resistance. Giventhe blood arteries surrounding the malignant tumour and the growing tumor's increasingoxygen requirements, certain malignancy cells are hypoxic. Chemotherapeutic drugs oftenfail to affect the hypoxic component of the tumor state. The result of hypoxia is anoxygenramp. A more aggressive phenotype is encouraged as a result of the increasedtumorheterogeneity. Moreover, overexpression has been found to be encouraged by a hypoxicenvironment. "Hypoxia inducible factor 1α (HIF-1α)," the primary protein involved inefflux, performs a crucial role.This technique effectively downregulates HIF-1α expression, makingMDR cells more susceptible to cancer therapy. NPs like PEGylated and non-PLGA-PEGPEGylated liposomes have useful applications.

8. Nanoparticles and proteomics-:

Proteins that combine to form the protein corona (PC) surround NPs when theyareintroduced to the biological system through serum and cells. The Vroman effect is what werefer to this. Therefore, developing the technology necessary It is critical to synthesiseNPs with the desired properties. Several proteomic techniques are used, including MS, SDS-PAGE, LC-MS, and isothermal microcalorimetry. The relationship between NPandthebiological environment, which regulates its utilization, is influenced by PC. serumor cellsthat promote prognosis, treatment, hunting proteins, and diagnostic biomarkers. Additionally, it helps understand the pathophysiology of cancer and the mechanismof resistancetomedications.

Post-translational changes, or PTMs, are crucial for spread.

8.1 Nanocarriers for siRNA -;

The delivery of siRNA siRNAs are small dsRNA molecules that decrease the expressionofthe target gene. They are about 21 nucleotides long. It is called "RNA interference." AALN-TTR01, two siRNA-based NPs that are presently being studied in clinical settings includeAtu027, targeting the transient thy protein to treat transthyretin-associated neurotoxicity.

8.2 Tumour small RNA analysis and shipment using nanomaterials- :

Small RNAs as family is naturally occurring "single-stranded non-RNA" control moleculesthe expression of position-Transcriptional genes is either inhibiting that productionofproteins by disrupting mRNA or preventing the target mRNA fromtranslating. Manyprofiling methods integrate enzyme activities from molecular biology with surface plasmon[17] resonance imaging or biosensors. MicroRNAs could be spread using nanotechnology.

Tradename	Material	Drug	Company	Indication	Year(s) approved
Doxil®	Liposome-PEG	Doxorubicin	Janssen	MBC, metastatic ovarian cancer	1995
Eligard®	PLGA	Leuprolide acetate	Tolmar	Prostate Cancer	2002
Abraxane®	Albumin	Paclitaxel	Celgene	Metastatic breast cancer	2005
Genexol PM®	mPEG-PLA	Paclitaxel	Samyang Corporation	Metastatic breast cancer	2007
Onivyde®	Liposome	Irinotecan	Merrimack	Pancreatic cancer	2015

8.3 DNA Nano technology for cancer therapy-:

Deoxyribonucleic acid sensors for identifying nucleic acids, DNA-based nanostructures fordrug delivery, DNA-coated particles of gold for lead detection by hybridisingthepb functional DNA enzyme to the attached DNA have been produced, as have scaffolds forassembling inorganic, and organic compounds and molecular into unique geometricmolecular conveyors.

9. merits of nanoparticles antineoplastic therapy -:

1.Developing NPs that target "macrophages" in particular and applying These are suggestedthat new medication transport system to circumvent this problem. Reducingandreprogramming TAMs, preventing macrophage recruitment, and using technological strategies that disrupt "CD47-SIRPα pathways" are currently commonly used. The problemsof NPs include equal optimization, performance, and scale-up synthesis. expectations. Thecircumvent is problem, NPs that particularly gole "macrophages" may be developedanduseto NDDS . Currently, TAM reduction and reprogramming, macrophage recruitment inhibition, 18]
and technological strategies that disrupt "CD47-SIRPα pathways"

2. For NPs to succeed clinically, these are crucial. Scaling up for big amounts is not alwaysfeasible, even with the equipment. extra factors. The most promising therapeutic candidatesthat have shown promise living beings tests They are neither generated or optimisedinasystematic manner.

3.targeted drug delivery
-nanoparticles reach only cancer cells of healthy cells this reducing side effects 4. less toxicity
-normal chemotherapy affects whole body
-nanopartical attack only tumour area so less damage &fewer side effects 5. controlled / slow drug release
-they release the drug slowly and steadily improving treat.

6. Better drug solubility
-some cancer drug are not soluble in water

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 1100-1110 www.ijprajournal.com ISSN: 2456-4494

-nanopartiles make them easily soluble better absorption in body . 7. improved Bioavaiblity
-more qty of drug reaches the blood stream & cancer site 8.lower dose required
-because they work more efficiently less drug quantity is needed 9. Enhanced penetration
-nanopartical can enter deep into tumour qty is needed

10. multifunctional therapy
-one nanoparticals can do diagnosis treatment together
Example . -: detect tumour +kill tumour both

III. CONCLUSION-:

Features of nanoparticles or pharmaceutical substances. Making "immunomodulatoryfactor loaded NPs." of immunotherapy vaccines also increase their effectiveness. Despite thefact that this is a relatively young subject, it is anticipated that nano-medicine drugs wouldismolecular research related to"mechanism of cancer origin, MDR, occurrence." Despitethevast quantity of study, only a handful While some are in clinical trials and several are inuse, most nano- medicines drugs are still in the experimental stage. Further research is requiredto"understand EPR, PC, toxicity, and physiological and cellular aspects that influenceNP-based drug delivery human body's "mechanism" in order to develop nanotechnology logically. Given the aforementioned information, we believe that the NP-based cancer treatment

Intracellular medication delivery: Certain nanoparticles are made to enter cancer cells anddeliver therapeutic payloads right inside of them. Targeting cancer cells that are difficult toreach or resistant can be particularly beneficial.

Personalized medicine: Nanomaterials' adaptability makes it possible to create customizedcancer treatments. Treatment results can be enhanced by customizing nanoparticlecharacteristics to a person's unique cancer kind and genetic composition. Minimally invasive surgery: Nanomaterials can make minimally invasive surgical methodspossible. With little harm to the surrounding tissue, nanorobots or nanocapsules canbecreated to carry out specific tasks like medicine administration or tumor removal. Although nanoparticles have the potential to treat cancer, there are issues with their safety, possible toxicity, and regulatory concerns. To guarantee the effectiveness and safety of these[19] materials in therapeutic applications, extensive research and stringent testing are necessary.

By permitting targeted drug delivery, which can boost medication efficacy while reducingside effects, nanoparticles present a promising approach to cancer therapy. By overcomingdrawbacks such drug resistance and lack of specificity, they are employed in immunotherapy, chemotherapy, radiation therapy, and photothermal therapy to enhance cancer treatment.
However, more research is needed to address issues including nanotoxicity and accumulationin the body. [20]

REFERENCES-:

[1]. Hannun, Y. A., Thompson, P., Wu, S., and Zhu, W. (2018). assessing both inherent andextrinsic risk factors for cancer. Communications in Nature, 9(1), 3490.
[2]. Sundaram, C., Harikumar, K. B., Tharakan, S. T., Kunnumakkara, A. B., Anand, P., Lai, O. S., Sung, B., & Aggarwal, B. B. (2008). Cancer can be avoided with significant lifestylemodifications. 2097–2116 in Pharmaceutical Research, 25(9).
[3]. American Cancer Society, 2021 Cancer Facts & Figures.
[4]. Park, W., Heo, YJ., & Han, D.K. Novel applications of nanoparticles in immunotherapyforcancer. In 2018, Biomater Res 22, 24. 10.1186/s40824-018 0133-y https://doi.org
[5]. Muyldermans, S., and Jovčevska, I. (2020). Nanobodies' Potential for TherapeuticUse. BioDrugs: Clinical Immunotherapeutics, Gene Therapy, and Biopharmaceuticals, 34(1), 11–26.
[6]. Ghiringhelli, F., Zitvogel, L., Kroemer, G., & Apetoh, L. (2008). elements of cancertreatment related to the immune system. reviews of nature. 59–73 in Immunology, 8(1)
[7]. Ismail, S., and Chan, H.-K. (2014). Clinical pharmacists' experiences, opinions, andinformational needs regarding the side effects of chemotherapy on cancer patients at a general hospital in Malaysia. 15 (13), 5305–5309, Asian Pacific Journal of Cancer Prevention.
[8]. A. Mahapatro and D.K. Singh. Drugs and vaccinations can be delivered site-directedlyinvivo using biodegradable

nanoparticles. (2011) J Nanobiotechnol 9, 55.

[9]. Zitvogel, L., and Kroemer, G. The microbiota's breakthrough. 2018; Nat Rev Immunol 18, 87–88.

[10]. Morgan, R. A., Dudley, M. E., Yang, J. C., Rosenberg, S. A., & Restifo, N. P. (2008). Aclinical route to successful cancer immunotherapy is adoptive cell transfer. Cancer, NatureReviews, 8(4), 299–308.

[11]. Rouzaut, A., Motz, G. T., Melero, I., & Coukos, G. (2014). One major barrier to effectivecancer immunotherapy is T-cell and NK-cell penetration into solid tumors. 522–526inCancer Discovery, 4(5).

[12]. Sibaud, V., and Lacouture, M. (2018). toxic side effects of immunotherapies andtargetedmedicines that impact the skin, hair, nails, and oral mucosa. Clinical dermatology in America, 19(Suppl 1), 31–39

[13]. Ankita Dadwal, Ashish Baldi, and Raj Kumar Narang (2018), Artificial Cells, Nanomedicine, and Biotechnology, 46:sup2, 295-305, Nanoparticles as carriers for drugdelivery in cancer

[14]. Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D. H., Zhang, H., Li, W., &Chen, Z. S. (2016). Molecular processes and innovative therapeutic pharmacological approaches forovercoming ABC transporter-mediated multidrug resistance. Reviews and commentaryondrug resistance in antibacterial and anticancer treatment, 27, 14–29

[15]. Loubaton, B., and Boisseau, P. (2011, September 1). ScienceDirect: NanomedicineandNanotechnology in Medicine.

[16]. Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., &Muller, R. (2008, June 11). Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications.

[17]. Tiwari, J. N. (August 14, 2011). Materials with nanostructures in zero, one, two, andthreedimensions for sophisticated electrochemical energy devices

[18]. Shin, WK., Cho, J., Kannan, A. et al. Mesoporous Methacrylate-FunctionalizedSiO2Nanoparticles for Cross-linked Composite Gel Polymer Electrolyte in Lithium-Ion PolymerBatteries. Science

[19]. Davidson, J. M., and A. Prokop (2008). intracellular delivery methods using nanovehicles. Pharmaceutical Sciences Journal, 97(9), 3518–3590

[20]. In 2014, February 12, Yang, Q., Jones, S., Parker, C., Zamboni, W., Bear, J., &Lai, S. Inorder to avoid immune cell uptake and clearance, PEG grafting must be done at densities that significantly beyond the brush conformation minimum.

[21]. A. Shafey (2020). An overview of the green synthesis of metal and metal oxidenanoparticles from plant leaf extracts and their uses. 304–339 in Green ProcessingandSynthesis, 9(1).

[22]. Ferreira, María, and Lassalle, Veronica. (2007). An overview of the preparationtechniques for PLA nanoparticles and microparticles for drug delivery. Micromolecularbiology.

[23]. Barar, J., and Omidi, Y. (2014). Targeting the tumor microenvironment: usingmultifunctional nanomedicines to penetrate the tumor interstitial fluid. Impacts ofBiotechnology

[24]. Omidi, Y., and J. Barar (2013). Cancer therapy is hampered by the tumormicroenvironment's dysregulated pH. 149-162 in BioImpacts: BI, 3(4).

[25]. Barar, J., & Omidi, Y. (2013). Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. BioImpacts : BI, 3(4), 149–162.